Literature DB >> 26345482

PMX53 protects spinal cord from ischemia-reperfusion injury in rats in the short term.

Q Dong1, L Sun2, L Peng3, B Yan3, J Lv1, G Wang3, S Gong1.   

Abstract

STUDY
DESIGN: Experimental study.
OBJECTIVES: To investigate the effect of pre-treatment with PMX53, a C5aR antagonist, on spinal cord ischemia-reperfusion injury (IRI) in rat.
SETTING: Department of Neurosurgery, Second Affiliated Hospital, Xi'an Jiaotong University School of Medicine, Xi'an, Shaanxi Province, China.
METHODS: IRI was induced in the lumbar spinal cord by applying a mini aneurysm clamp to the abdominal aorta for 60 min in adult Sprague-Dawley rats. PMX53 (1 mg kg(-1)) was administered through femoral vein injection 30 min before ischemia on the rats in the PMX53 group (n=18). The saline group (n=18) was given saline at the same volume through femoral vein injection. The neurologic outcome of the posterior limbs was assessed by the Basso-Beattie-Bresnahan (BBB) score at 1, 6, 12, 24 and 48 h after reperfusion. Histologic changes of the spinal cord were detected with hematoxylin-eosin (H-E) staining. Enzyme-linked immunosorbent assay (ELISA) was used to detect myeloperoxidase (MPO) activity in the spinal cord. Immunohistochemistry was used to investigate the quantity of activated astrocytes and microglia.
RESULTS: After pre-treatment with PMX53, neurologic function improved gradually after 6, 12, 24 and 48 h reperfusion. The BBB score of the PMX53 group increased significantly (P<0.05) compared with the saline group. H-E staining showed that pathologic damage in the PMX53 group was reduced. Moreover, administration of PMX53 significantly inhibited neutrophil infiltration in the spinal cord. Levels of MPO activity in the spinal cord were remarkably lower in the PMX53 group (P<0.05). There were also more activated microglia and astrocytes in the spinal cord of the PMX53 group than in the saline group (P<0.05).
CONCLUSION: PMX53 delivered 30 min prior to ischemic injury protects the spinal cord from IRI, probably via the inhibition of neutrophil activity, increased activated microglia and astrocyte.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26345482     DOI: 10.1038/sc.2015.146

Source DB:  PubMed          Journal:  Spinal Cord        ISSN: 1362-4393            Impact factor:   2.772


  32 in total

Review 1.  Free radical pathways in CNS injury.

Authors:  A Lewén; P Matz; P H Chan
Journal:  J Neurotrauma       Date:  2000-10       Impact factor: 5.269

2.  Microglial C5aR (CD88) expression correlates with amyloid-beta deposition in murine models of Alzheimer's disease.

Authors:  Rahasson R Ager; Maria I Fonseca; Shu-Hui Chu; Sam D Sanderson; Stephen M Taylor; Trent M Woodruff; Andrea J Tenner
Journal:  J Neurochem       Date:  2010-02-02       Impact factor: 5.372

Review 3.  Prevention of endothelial cell injury by activated protein C: the molecular mechanism(s) and therapeutic implications.

Authors:  Kenji Okajima
Journal:  Curr Vasc Pharmacol       Date:  2004-04       Impact factor: 2.719

4.  The complement factor C5a contributes to pathology in a rat model of amyotrophic lateral sclerosis.

Authors:  Trent M Woodruff; Kerina J Costantini; James W Crane; Julie D Atkin; Peter N Monk; Stephen M Taylor; Peter G Noakes
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

5.  Complement: a novel factor in basal and ischemia-induced neurogenesis.

Authors:  Yalda Rahpeymai; Max Albert Hietala; Ulrika Wilhelmsson; Andrew Fotheringham; Ioan Davies; Ann-Katrin Nilsson; Jörg Zwirner; Rick A Wetsel; Craig Gerard; Milos Pekny; Marcela Pekna
Journal:  EMBO J       Date:  2006-02-23       Impact factor: 11.598

6.  Role of complement anaphylatoxin receptors (C3aR, C5aR) in the development of the rat cerebellum.

Authors:  Magalie Bénard; Emilie Raoult; David Vaudry; Jérome Leprince; Anthony Falluel-Morel; Bruno J Gonzalez; Ludovic Galas; Hubert Vaudry; Marc Fontaine
Journal:  Mol Immunol       Date:  2008-07-16       Impact factor: 4.407

7.  Systemic administration of interleukin-10 attenuates early ischemic response following spinal cord ischemia reperfusion injury in rats.

Authors:  H Hakan Oruckaptan; Pinar Ozisik; Pergin Atilla; Muruvet Tuncel; Kamer Kilinc; Pinar Ozdemir Geyik; Nursen Basaran; Eser Yüksel; O Ekin Ozcan
Journal:  J Surg Res       Date:  2008-10-10       Impact factor: 2.192

8.  Protective effect of C5a receptor inhibition after murine reperfused stroke.

Authors:  Grace H Kim; J Mocco; David K Hahn; Christopher P Kellner; Ricardo J Komotar; Andrew F Ducruet; William J Mack; E Sander Connolly
Journal:  Neurosurgery       Date:  2008-07       Impact factor: 4.654

9.  Minimum information about a spinal cord injury experiment: a proposed reporting standard for spinal cord injury experiments.

Authors:  Vance P Lemmon; Adam R Ferguson; Phillip G Popovich; Xiao-Ming Xu; Diane M Snow; Michihiro Igarashi; Christine E Beattie; John L Bixby
Journal:  J Neurotrauma       Date:  2014-07-11       Impact factor: 5.269

Review 10.  Development and treatments of inflammatory cells and cytokines in spinal cord ischemia-reperfusion injury.

Authors:  Ping Zhu; Jia-xin Li; Masayuki Fujino; Jian Zhuang; Xiao-Kang Li
Journal:  Mediators Inflamm       Date:  2013-07-14       Impact factor: 4.711

View more
  3 in total

1.  Histological Findings After Aortic Cross-Clamping in Preclinical Animal Models.

Authors:  Hamdy Awad; Alexander Efanov; Jayanth Rajan; Andrew Denney; Bradley Gigax; Peter Kobalka; Hesham Kelani; D Michele Basso; John Bozinovski; Esmerina Tili
Journal:  J Neuropathol Exp Neurol       Date:  2021-10-26       Impact factor: 3.685

2.  Novel Therapeutic Effects in Rat Spinal Cord Injuries: Recovery of the Definitive and Early Spinal Cord Injury by the Administration of Pentadecapeptide BPC 157 Therapy.

Authors:  Darko Perovic; Marija Milavic; Stjepan Dokuzovic; Ivan Krezic; Slaven Gojkovic; Hrvoje Vranes; Igor Bebek; Vide Bilic; Nenad Somun; Ivan Brizic; Ivan Skorak; Klaudija Hriberski; Suncana Sikiric; Eva Lovric; Sanja Strbe; Milovan Kubat; Alenka Boban Blagaic; Anita Skrtic; Sven Seiwerth; Predrag Sikiric
Journal:  Curr Issues Mol Biol       Date:  2022-04-27       Impact factor: 2.976

Review 3.  Nanofiber Scaffolds as Drug Delivery Systems to Bridge Spinal Cord Injury.

Authors:  Angela Faccendini; Barbara Vigani; Silvia Rossi; Giuseppina Sandri; Maria Cristina Bonferoni; Carla Marcella Caramella; Franca Ferrari
Journal:  Pharmaceuticals (Basel)       Date:  2017-07-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.